Drugs / INO-9112
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05430958 | Oct 2022 → Mar 2024 | COVID-19 | Inovio Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02431312 | Jan 2015 → May 2018 | chronic hepatitis B virus infection | Inovio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-9112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02431312 ↗ |
| Route | Intramuscular | “Delivered IM Followed by EP” NCT02431312 ↗ |